You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
7 September 2021
Dr. John Stagg, a world-leader in the adenosine pathway, joins Scientific Advisory Board of Tarus Therapeutics, Inc.
27 May 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
28 April 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
6 April 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
10 March 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
2 December 2020
Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci